FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
01. Dezember 2022 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights
08. November 2022 08:00 ET
|
Nuvectis Pharma, Inc.
The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 2023 Investigational New Drug...
Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
18. Oktober 2022 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
03. Oktober 2022 16:30 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
28. September 2022 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment...
Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
13. September 2022 08:30 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
07. September 2022 08:30 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights
05. August 2022 08:00 ET
|
Nuvectis Pharma, Inc.
NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in...
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
01. August 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
27. Juli 2022 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...